Skip to main content

Table 3 Multivariate analyses of local progression-free survival (LPFS)

From: A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression

  Hazard ratio 95% confidence interval p-value
Interval between initial tumor diagnosis and RT of MSCC (≤15 vs. > 15 months) 0.87 0.74–1.03 0.12
Visceral metastases at the time of RT (no vs. yes) 0.56 0.39–0.78 < 0.001
Other bone metastases at the time of RT (no vs. yes) 1.41 0.96–2.10 0.08
Type of primary tumor (breast cancer vs. prostate cancer vs. myeloma/lymphoma vs. lung cancer vs. unknown primary vs. renal cell carcinoma vs. colorectal cancer vs. other tumors) 1.91 1.17–3.09 0.009
Time developing motor deficits prior to RT (1–7 vs. 8–14 vs. > 14 days) 0.48 0.32–0.71 < 0.001
Gait function prior to RT (not ambulatory vs. ambulatory) 0.81 0.58–1.12 0.19
Number of vertebrae affected by MSCC (1–2 vs. 3–4 vs. ≥5) 1.28 0.82–1.98 0.27
ECOG performance score (1–2 vs. 3 vs. 4) 1.57 1.12–2.18 0.009
  1. Bold values = significant p-values